Home News Company in the news

Singapore eDevelopment subsidiary and research partner GRDG Sciences valued at $1.97 bil

Felicia Tan
Felicia Tan6/1/2020 08:37 AM GMT+08  • 2 min read
Singapore eDevelopment subsidiary and research partner GRDG Sciences valued at $1.97 bil
Impact Biomedical’s ownership in the suite is estimated to be at $1.32 billion.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (June 1): Singapore eDevelopment (SeD) announced on Monday that its wholly-owned subsidiary Impact Biomedical’s suite of antiviral and medical technologies, which is co-owned by its scientific research partner, Global Research and Discovery Group Sciences (GRDG Sciences), is valued at $1.97 billion.

The valuation was conducted by independent experts who specialise in assessing the potential deal value of medical intellectual property.

Impact Biomedical’s ownership in the suite is estimated to be at $1.32 billion.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.